

NEW ORAL oral formulation glucagon-like peptide 1 (GLP1) SEMAGLUTIDE

Raffaele La Porta¹, Giovanni Granata², Francesco Ferrara³, and Antonio Vitiello⁴

¹ASUR Marche

²Local Health Authority Salerno

³USL 1 Umbria

⁴Azienda Unità Sanitaria Locale Umbria 1

April 28, 2020

Abstract

In recent years, new classes of drugs have entered the market for the treatment of type 2 diabetes mellitus (T2DM) with good efficacy on the normalization of blood glucose and with a reduction in the risk of hypoglycaemia and with significant effects on weight reduction. One of the most promising classes in achieving these goals was that of the agonists (GLP)-1. However, a difficulty in using these drugs arises from subcutaneous administration, a route that is not very convenient for users and with the risk of infections. More recently, a GLP-1 agonist, semaglutide, has been developed which can be administered orally. In this review article, we discussed the effectiveness of GLP-1 agonists, oral semaglutide and its therapeutic potential.

Hosted file

SEMAGLUTIDE OR- 2.pdf available at <https://authorea.com/users/310211/articles/441019-new-oral-oral-formulation-glucagon-like-peptide-1-glp1-semaglutide>